 |
Video: What is a Stock Split?
|
 |
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. Co.'s lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. According to our JSPR split history records, Jasper Therapeutics has had 1 split. | |
 |

Jasper Therapeutics (JSPR) has 1 split in our JSPR split history database. The split for JSPR took place on January 04, 2024. This was a 1 for 10 reverse split, meaning for each 10 shares of JSPR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as Jasper Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the JSPR split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Jasper Therapeutics shares, starting with a $10,000 purchase of JSPR, presented on a split-history-adjusted basis factoring in the complete JSPR split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/13/2020 |
|
End date: |
02/10/2025 |
|
Start price/share: |
$98.20 |
|
End price/share: |
$5.98 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-93.91% |
|
Average Annual Total Return: |
-42.34% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$609.14 |
|
Years: |
5.08 |
|
|
 |
Date |
Ratio |
01/04/2024 | 1 for 10 |
|
 |